Section Arrow
SYRE.NASDAQ
- Spyre Therapeutics
Quotes are at least 15-min delayed:2026/09/04 18:55 EDT
After Hours
Last
 87.21
-1.77 (-1.99%)
Bid
56
Ask
90.75
High 90.75 
Low 87.21 
Volume 104.03K 
Regular Hours (Closed)
Last
 88.98
+1.73 (+1.98%)
Day High 
89.18 
Prev. Close
87.25 
1-M High
110.175 
Volume 
803.85K 
Bid
56
Ask
90.75
Day Low
84.68 
Open
86.45 
1-M Low
84 
Market Cap 
7.69B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 95.02 
20-SMA 100.09 
50-SMA 98.07 
52-W High 110.175 
52-W Low 14.505 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.92/-4.25
Enterprise Value
7.69B
Balance Sheet
Book Value Per Share
10.83
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
IMRNImmuron Limited1.8+0.69+62.16%-- 
After Hours 1.72 -0.08 -4.44%
RXRXRecursion Pharmaceuticals3.63+0.19+5.52%-- 
After Hours 3.6545 +0.0245 +0.67%
CMNDClearmind Medicine Inc.1.16-0.54-31.76%-- 
After Hours 1.1599 -0.0001 -0.01%
MRNAModerna145.55-3.32-2.23%-- 
After Hours 144.98 -0.57 -0.39%
RAREUltragenyx Pharmaceutical15.3+0.45+3.03%-- 
After Hours 15.3505 +0.0505 +0.33%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.